High body mass index and allergies in schoolchildren: the French six cities study

BMJ Open Resp Res 2014;1:e000054 doi:10.1136/bmjresp-2014-000054

• Respiratory epidemiology

1. Danielle Saadeh1,7, 
2. Pascale Salameh1, 
3. Denis Caillaud2, 
4. Denis Charpin3, 
5. Frédéric de Blay4,
6. Christine Kopferschmitt4, 
7. François Lavaud5, 
8. Isabella Annesi-Maesano6, 
9. Isabelle Baldi7 and
10. Chantal Raherison7,8

+Author Affiliations

1. ¹Clinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Lebanese University, Hadath, Lebanon
2. ²Hôpital Gabriel Montpied, Clermont-Ferrand, France
3. ³Hôpital Nord, Marseille, France
4. ⁴Hôpital Civil, Strasbourg, France
5. ⁵Hôpital Maison Blanche, Reims, France
6. ⁶EPAR, UMR-S 1136, Institute Pierre Louis of Epidemiology and Public Health, INSERM and UPMC Sorbonne Universites, Paris, France
7. ⁷INSERM U897, Institut de Santé Publique d'Epidémiologie et de Développement, Université de Bordeaux, Bordeaux, France
8. ⁸Service des maladies respiratoires, Hôpital du Haut-Lévèque, Avenue de Magellan, Pessac, France

1. Correspondence toDanielle Saadeh; daniellesaadeh@hotmail.com

• Received 23 July 2014
• Accepted 3 October 2014
• Published 24 December 2014

Abstract

Background The prevalence of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis is increasing rapidly worldwide, especially among children and in western countries. This coincides with an increase in body mass index (BMI), which might be a major risk factor for atopic diseases.

Clinical Documentation in the 21st Century: Executive Summary of a Policy Position Paper From the American College of Physicians

• PDF

Position Papers | 13 January 2015

FREE ONLINE FIRST

Thomson Kuhn, MA; Peter Basch, MD; Michael Barr, MD, MBA; Thomas Yackel, MD, MPH, MS, for the Medical Informatics Committee of the American College of Physicians*

[+] Article and Author Information

See Also:

• Clinical Documentation to Improve Patient Care

Ann Intern Med. Published online 13 January 2015 doi:10.7326/M14-2128

Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization

Short report

Katinka Ónodi-Nagy, Ágnes Kinyó, Angéla Meszes, Edina Garaczi, Lajos Kemény and Zsuzsanna Bata-Csörg¿

Allergy, Asthma & Clinical Immunology 2015, 11:1  doi:10.1186/1710-1492-11-1

Published: 9 January 2015

Abstract (provisional)

Background

It hasn't been clearly understood yet whether sensitization to antibiotics, the virus itself or transient loss of drug tolerance due to the virus, is responsible for the development of maculopapular exanthems following amoxicillin intake in patients with infectious mononucleosis. We aimed to examine whether sensitization to penicillin developed among patients with skin rash following amoxicillin treatment within infectious mononucleosis.

Allergy to sunflower seed and sunflower butter as proposed vehicle for sensitization

Case report

Elana Lavine^1* and Moshe Ben-Shoshan²

Allergy, Asthma & Clinical Immunology 2015, 11:2  doi:10.1186/s13223-014-0065-6

Published: 8 January 2015

Abstract (provisional)

Background

It is hypothesized that household exposure to allergenic proteins via an impaired skin barrier, such as atopic dermatitis, may contribute to the development of IgE sensitization. Household presence of peanut is a risk factor for the development of peanut allergy in children. Sunflower seed butter is a peanut-free alternative to peanut butter, and sunflower seed allergy is an uncommon but reported entity.

The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Immunology Letters

Volume 162, Issue 2, Part B, December 2014, Pages 185–193

Dutch Society for Immunology 1964 – 2014 — Special issue on the occasion of the 50th anniversary of the Dutch Society for Immunology (NVVI)

• Fulvio Braido^a, 
• Giovanni Melioli^a, , , 
• Piero Candoli^b, 
• Andrea Cavalot^c, 
• Mario Di Gioacchino^d, 
• Vittorio Ferrero^e, 
• Cristoforo Incorvaia^f, 
• Carlo Mereu^g, 
• Erminia Ridolo^h, 
• Giovanni Rollaⁱ, 
• Oliviero Rossi^j, 
• Eleonora Savi^k, 
• Libero Tubino^l, 
• Giorgio Reggiardo^m, 
• Ilaria Baiardini^a, 
• Eddi di Marcoⁿ, 
• Gilberto Rinaldi^o, 
• Giorgio Walter Canonica^a, 
• Lantigen Study Group, 
• Carlo Accorsi^c, 
• Claudia Bossilinoⁱ, 
• Laura Bonzano^h, 
• Michela DiLizia^d, 
• Barbara Fedrighini^c, 
• Valentina Garelli^a, 
• Vincenzo Gerace^l, 
• Sara Maniscalco^g, 
• Ilaria Massaro^j,
• Alessandro Messi^b, 
• Manlio Milanese^g, 
• Silvia Peveri^k, 
• Arminio Penno^c,

 Show more

doi:10.1016/j.imlet.2014.10.026

Get rights and content

Under a Creative Commons license

  Open Access

---

Highlights

•

Old trials on LantigenB (LB) showed its effect on recurrent respiratory infections.

•

These studies were performed using non-updated clinical and statistical methods.

•

Here we show that LB reduces the number of infections in a phase IV clinical study.

•

LB represents a real first-line prophylaxis of recurrent respiratory infections.